192 related articles for article (PubMed ID: 26081614)
21. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and intensive treatment of acute leukemia in pregnancy].
Sierra J; Urbano Ispizua A; Cararach V; Carreras E; Fortuny A; Grañena A; Rozman C
Med Clin (Barc); 1987 Jan; 88(1):28-31. PubMed ID: 3469488
[No Abstract] [Full Text] [Related]
23. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M; Wijermans PW; Kicinski M; Chantepie S; Van der Velden WJFM; Noppeney R; Griškevičius L; Neubauer A; Crysandt M; Vrhovac R; Luppi M; Fuhrmann S; Audisio E; Candoni A; Legrand O; Foà R; Gaidano G; van Lammeren-Venema D; Posthuma EFM; Hoogendoorn M; Giraut A; Stevens-Kroef M; Jansen JH; de Graaf AO; Efficace F; Ammatuna E; Vilque JP; Wäsch R; Becker H; Blijlevens N; Dührsen U; Baron F; Suciu S; Amadori S; Venditti A; Huls G;
Lancet Haematol; 2023 Nov; 10(11):e879-e889. PubMed ID: 37914482
[TBL] [Abstract][Full Text] [Related]
24. Delivery for women with a previous cesarean: guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF).
Sentilhes L; Vayssière C; Beucher G; Deneux-Tharaux C; Deruelle P; Diemunsch P; Gallot D; Haumonté JB; Heimann S; Kayem G; Lopez E; Parant O; Schmitz T; Sellier Y; Rozenberg P; d'Ercole C
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):25-32. PubMed ID: 23810846
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
26. [Delivery of a normal child after chemotherapy of acute promyelocytic leukaemia during pregnancy (author's transl)].
Gstöttner M; Frisch H; Dienstl F
Blut; 1978 Mar; 36(3):171-4. PubMed ID: 273452
[TBL] [Abstract][Full Text] [Related]
27. [Acute myelogenous leukemia developed at the 26th week of gestation].
Tashiro H; Umezawa K; Shirota M; Oka Y; Shirasaki R; Nishi R; Taguchi A; Akiyama N; Kawasugi K; Ayabe T; Shirafuji N
Rinsho Ketsueki; 2011 Jan; 52(1):18-22. PubMed ID: 21378477
[TBL] [Abstract][Full Text] [Related]
28. Treatment of acute myeloid leukemia during pregnancy.
Chang A; Patel S
Ann Pharmacother; 2015 Jan; 49(1):48-68. PubMed ID: 25258419
[TBL] [Abstract][Full Text] [Related]
29. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer, pregnancy, and breastfeeding.
Helewa M; Lévesque P; Provencher D; Lea RH; Rosolowich V; Shapiro HM;
J Obstet Gynaecol Can; 2002 Feb; 24(2):164-80; quiz 181-4. PubMed ID: 12196882
[TBL] [Abstract][Full Text] [Related]
31. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy-induced fetal anemia in maternal acute myelocytic leukemia].
Hoopmann M; Rahimi G; Hartlapp I; Eifinger F; Garnier Y; Bald R
Ultraschall Med; 2008 Aug; 29(4):424-7. PubMed ID: 17717788
[TBL] [Abstract][Full Text] [Related]
33. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
[TBL] [Abstract][Full Text] [Related]
35. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Wang L; Lin N
Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
[TBL] [Abstract][Full Text] [Related]
36. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.
Dellinger RP; Levy MM; Rhodes A; Annane D; Gerlach H; Opal SM; Sevransky JE; Sprung CL; Douglas IS; Jaeschke R; Osborn TM; Nunnally ME; Townsend SR; Reinhart K; Kleinpell RM; Angus DC; Deutschman CS; Machado FR; Rubenfeld GD; Webb S; Beale RJ; Vincent JL; Moreno R;
Intensive Care Med; 2013 Feb; 39(2):165-228. PubMed ID: 23361625
[TBL] [Abstract][Full Text] [Related]
37. Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Mahdi AJ; Gosrani D; Chakraborty M; Rees A; Conner C; Wilson K; Rayment R; Alvares C
Br J Haematol; 2018 Feb; 180(4):603-604. PubMed ID: 27766617
[No Abstract] [Full Text] [Related]
38. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.
Dellinger RP; Levy MM; Rhodes A; Annane D; Gerlach H; Opal SM; Sevransky JE; Sprung CL; Douglas IS; Jaeschke R; Osborn TM; Nunnally ME; Townsend SR; Reinhart K; Kleinpell RM; Angus DC; Deutschman CS; Machado FR; Rubenfeld GD; Webb SA; Beale RJ; Vincent JL; Moreno R;
Crit Care Med; 2013 Feb; 41(2):580-637. PubMed ID: 23353941
[TBL] [Abstract][Full Text] [Related]
39. Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia--neonatal and infantile course.
Artlich A; Möller J; Tschakaloff A; Schwinger E; Kruse K; Gortner L
Eur J Pediatr; 1994 Jul; 153(7):488-91. PubMed ID: 7957364
[TBL] [Abstract][Full Text] [Related]
40. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians.
Vayssière C; Sentilhes L; Ego A; Bernard C; Cambourieu D; Flamant C; Gascoin G; Gaudineau A; Grangé G; Houfflin-Debarge V; Langer B; Malan V; Marcorelles P; Nizard J; Perrotin F; Salomon L; Senat MV; Serry A; Tessier V; Truffert P; Tsatsaris V; Arnaud C; Carbonne B
Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():10-8. PubMed ID: 26207980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
